Journal of Cancer Research and Clinical Oncology最新文献

{"title":"¹⁸F-FDG PET radiomics score construction by automatic machine learning for treatment response prediction in elderly patients with diffuse large B-cell lymphoma: a multicenter study.","authors":"Jincheng Zhao, Wenzhuo Zhao, Man Chen, Jian Rong, Yue Teng, Jianxin Chen, Jingyan Xu","doi":"10.1007/s00432-025-06172-3","DOIUrl":"10.1007/s00432-025-06172-3","url":null,"abstract":"<p><strong>Purpose: </strong>To explore the development and validation of automated machine learning (AutoML) models for ¹⁸F-FDG PET imaging-based radiomics signatures to predict treatment response in elderly patients with diffuse large B-cell lymphoma (DLBCL).</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 175 elderly (≥ 60 years) DLBCL patients diagnosed between March 2015 and March 2023 at two medical centers, with a total of 1010 lesions. The baseline PET imaging-based radiomics features of the training cohort were processed using AutoML model AutoGluon to generate a radiomics score (radscore) and predict treatment response at the lesion and patient levels. Furthermore, a multivariable logistic analysis was used to design and evaluate a multivariable model in the training and validation cohorts.</p><p><strong>Results: </strong>ROC curve analysis showed that the radscore generated by AutoML exhibited higher accuracy in predicting treatment response at the lesion level compared to metabolic parameters (SUVmax, MTV, and TLG) in both the training group (AUC: 0.791, 0.542, 0.667, 0.651, respectively) and the validation group (AUC: 0.712, 0.616, 0.639, 0.657, respectively). Multivariable logistic analysis indicated that NCCN-IPI (OR = 5.427, 95% CI: 1.163-25.317), BCL-2 (OR = 3.714, 95% CI: 1.406-9.816), TMTV (OR = 4.324, 95% CI: 1.095-17.067), and avg-radscore (OR = 3.176, 95% CI: 1.313-7. 686) were independent predictors of treatment response. The multivariable model comprising NCCN-IPI, BCL-2, TMTV, and avg-radscore outperformed conventional models and clinical-pathological models in predicting treatment response. (P<0.05).</p><p><strong>Conclusion: </strong>The radscore generated by AutoML can predict the treatment response of elderly DLBCL patients, potentially aiding in clinical decision-making.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 3","pages":"125"},"PeriodicalIF":2.7,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11953086/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143736050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increasing cisplatin exposure promotes small-cell lung cancer transformation after a shift from glucose metabolism to fatty acid metabolism.","authors":"Qiu-Yu Zhao, Wen-Jun Liu, Jian-Guang Wang, He Li, Jia-Lu Lv, Yumeng Wang, Chun Wang","doi":"10.1007/s00432-025-06164-3","DOIUrl":"10.1007/s00432-025-06164-3","url":null,"abstract":"<p><strong>Objectives: </strong>Lung cancer is a leading cause of global cancer mortality. Clinical observations reveal that histological transformation from non-small cell lung cancer (NSCLC) to small cell lung cancer (SCLC) is accompanied by mutations in TP53 and RB1. By applying gradually increasing cisplatin concentrations to mimic the escalating drug pressure within the tumor microenvironment, this study investigated the link between phenotypic transformation to SCLC in cisplatin-resistant human lung adenocarcinoma cells and alterations in cellular energy production pathways.</p><p><strong>Materials and methods: </strong>We established two cisplatin-resistant NSCLC cell lines with varying resistance levels. RNAseq analyses identified TP53 and RB1 gene mutations. Comprehensive functional assays were performed to characterize A549/DDP1 μg/mL and A549/DDP3 μg/mL cells, focusing on proliferation and migratory capabilities. Cellular bioenergetics were assessed through glycolysis and oxidative phosphorylation analyses. Western blotting was employed to examine epithelial-mesenchymal transition (EMT), glucose metabolism, and lipid metabolism markers. Cell cycle distribution was analyzed by flow cytometry. Additionally, a xenograft mouse model was developed for in vivo validation.</p><p><strong>Results: </strong>TP53 and RB1 mutations were associated with cisplatin concentration-dependent phenotypic transformation, with A549/DDP cells acquiring a more aggressive SCLC-like phenotype (In the article we call the A549/DDPSCLC cells). Analysis of cell bioenergetics profiling and Western blot analyses revealed enhanced glucose metabolism in A549/DDP1 μg/mL cells, while A549/DDPSCLC cells exhibited predominant lipid metabolism. Compound3K and Etomoxir specifically inhibit the activity of PKM2 and CPT1A, respectively, with Etomoxir demonstrating substantially inhibited A549/DDPSCLC cells growth and more cell cycle arrest in the G0/G1 phase. Combinatorial of Compound3K and Etomoxir effectively induced cell death in A549/DDPSCLC phenotype cells in vitro. Etomoxir alone or combined with Compound3K significantly inhibited tumor growth in vivo, with enhanced efficacy in the combination group.</p><p><strong>Conclusions: </strong>This study provides the first evidence of cisplatin concentration-dependent metabolic reprogramming during NSCLC-to-SCLC transformation. We identified a phenotypic transition from NSCLC to SCLC accompanied by a metabolic shift from glucose to fatty acid metabolism, offering new insights into therapeutic strategies for treatmentresistant lung cancer.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 3","pages":"126"},"PeriodicalIF":2.7,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11953189/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Sequential treatment of metastatic renal cell carcinoma patients after first-line vascular endothelial growth factor targeted therapy in a real-world setting: epidemiologic, noninterventional, retrospective-prospective cohort multicentre study.","authors":"Alvydas Cesas, Vincas Urbonas, Skaiste Tulyte, Rasa Janciauskiene, Sigita Liutkauskiene, Ingrida Grabauskyte, Ignas Gaidamavicius","doi":"10.1007/s00432-025-06161-6","DOIUrl":"10.1007/s00432-025-06161-6","url":null,"abstract":"","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 3","pages":"121"},"PeriodicalIF":2.7,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11937152/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does anxiety influence the use of complementary or alternative medicine among cancer patients?","authors":"Caroline Heyder, Judith Büntzel, Hristo Boyadzhiev, Petra Stegmaier, Bijan Zomorodbakhsch, Klaus Heißner, Christoph Stoll, Ludwig Fischer von Weikersthal, Jana Czekay, Ivonne Rudolph, Jutta Hübner","doi":"10.1007/s00432-025-06173-2","DOIUrl":"10.1007/s00432-025-06173-2","url":null,"abstract":"<p><strong>Purpose: </strong>The aim of this study was to investigate the extent to which patients' anxiety due to their cancerous disease has an influence on the use of complementary and alternative medicine (CAM) methods.</p><p><strong>Methods: </strong>230 patients completed an anonymous voluntary questionnaire that was sent to outpatient oncological facilities participating in the survey. This questionnaire included standardised tests such as the Allgemeine Selbstwirksamkeit Kurzskala (ASKU, self-efficacy short scale) and the State-Trait-Anxiety-Inventory (STAI) as well as socio-demographic information and a section on CAM use. Statistical analyses and regression models were used to identify correlations.</p><p><strong>Results: </strong>Female gender, high level of education (high school diploma or university degree) and increased trait anxiety were related to CAM use. All other variables analysed showed no significant results.</p><p><strong>Conclusion: </strong>This study demonstrates that trait anxiety and sociodemographic factors significantly influence CAM usage among cancer patients. Physicians and health care providers should consider this in consultations to guarantee the best possible care for patients.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 3","pages":"123"},"PeriodicalIF":2.7,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11937123/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dual targeting of Aurora Kinase A and poly (ADP-ribose) polymerase as a therapeutic option for patients with ovarian cancer: preclinical evaluations.","authors":"Soumya M Turaga, Stacey L Hembruff, Masha G Savelieff, Arnab Ghosh, Rajni V Puri, Harsh B Pathak, Linda J Paradiso, Thomas J Myers, Ao Li, Andrew K Godwin","doi":"10.1007/s00432-025-06152-7","DOIUrl":"10.1007/s00432-025-06152-7","url":null,"abstract":"<p><strong>Purpose: </strong>Epithelial ovarian cancers (EOCs) are often diagnosed at an advanced stage, leading to poor survival outcomes despite chemotherapeutic and surgical advances. Precision oncology strategies have been developed to treat EOCs characterized by BRCA1 and BRCA2 inactivation with consequent homologous recombination (HR) repair defects. HR deficiency enhances tumor sensitivity to poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis), approved for EOCs as maintenance therapy, although they have been discontinued as recurrent EOC monotherapy. However, combination treatment with PARPis may be a viable alternate strategy for EOCs. Moreover, EOC patients with wild-type BRCA are ineligible for PARPs, necessitating novel approaches. We previously discovered that inhibiting Aurora kinase A (AURKA) downregulates PARP and BRCA1/2 expression in EOCs and may constitute a viable approach for EOCs.</p><p><strong>Methods: </strong>Herein, we evaluated combined PARPi olaparib with the selective AURKA inhibitor (AURKAi) VIC-1911 in six different patient-derived xenograft (PDX) EOC models, including two with mutant BRCA1, two with mutant BRCA2, one with mutant BRCA1/2, and one with wild-type BRCA1/2.</p><p><strong>Results: </strong>We found that combined olaparib + VIC-1911 treatment reduced tumor volumes and weights by up 90% in some PDX models, with synergistic effect compared to olaparib and VIC-1911 monotherapy. Additionally, combined olaparib + VIC-1911 treatment improved survival of mice harboring both mutant BRCA1 and wild-type BRCA1/2 PDXs. Generally, mice tolerated the drug combinations well during treatment, though loss of body weight was observed at higher drug dosages and with intensive treatment regimens.</p><p><strong>Conclusion: </strong>Our studies indicate a synergistic benefit from combined PARPi and AURKAi in mutant and wild-type BRCA EOC tumors.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 3","pages":"124"},"PeriodicalIF":2.7,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11946953/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143730197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of an appropriate reference gene for normalization of qRT-PCR expression analyses in human breast cancer cell lines: application to L-arginine depletion studies.","authors":"Antonia Röglin, Rainer Böger, Fiona Kleinsang, Juliane Hannemann","doi":"10.1007/s00432-025-06165-2","DOIUrl":"10.1007/s00432-025-06165-2","url":null,"abstract":"<p><strong>Purpose: </strong>Quantitative real-time PCR (qRT-PCR) represents a robust methodology to investigate alterations in gene expression patterns during tumorigenesis. The quantification of target gene expression is conventionally standardized through normalization against a stably expressed reference gene. However, the expression profile of a specific reference gene can exhibit variability across different tissue types and diverse physiological conditions. This study aimed to identify a suitable reference gene from a pool of ten potential candidates for the comparison of gene expression profiles between six human breast cell lines, comprising both normal breast (MCF-12A) and breast cancer cells (MCF-7, BT-474, SK-BR-3, MDA-MB-468, MDA-MB-231).</p><p><strong>Methods: </strong>Four different mathematical approaches were used to calculate the stability of reference gene expression (comparative ΔCt method, NormFinder, coefficient of variation and RefFinder).</p><p><strong>Results: </strong>Stability analysis identified ACTB as a suitable reference gene across all cell lines. As we are specifically interested in studying metabolic adaptation of breast cancer, we applied the same approach to identify a suitable reference gene also after maintaining the cell lines in L-arginine-deficient medium for up to 72 h. The stability ranking of reference genes fluctuated after L-arginine was depleted.</p><p><strong>Conclusion: </strong>In the context of investigating specific cell lines under certain conditions, we propose the identification of reference genes that exhibit optimal stability and suitability.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 3","pages":"122"},"PeriodicalIF":2.7,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11937119/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Comparison of robotic-assisted and laparoscopic partial nephrectomy based on the PADUA score and the predictive value of the PADUA score and the Mayo Adhesive Probability score for postoperative complications: a single-center retrospective study.","authors":"Shuo Liu, Bowen Zhang, Bowen Weng, Xiangqiang Liu, Sichuan Hou","doi":"10.1007/s00432-025-06170-5","DOIUrl":"10.1007/s00432-025-06170-5","url":null,"abstract":"","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 3","pages":"120"},"PeriodicalIF":2.7,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11937157/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction Note: Significances of contactin‑1 expression in human gastric cancer and knockdown of contactin‑1 expression inhibits invasion and metastasis of MKN45 gastric cancer cells.","authors":"De-Hu Chen, Ji-Wei Yu, Ju-Gang Wu, Shou-Lian Wang, Bo-Jian Jiang","doi":"10.1007/s00432-025-06166-1","DOIUrl":"10.1007/s00432-025-06166-1","url":null,"abstract":"","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 3","pages":"119"},"PeriodicalIF":2.7,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11937210/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genomic analysis of small renal masses reveals mutations linked with renal cell carcinoma and fast-growing tumors.","authors":"Ieva Vaicekauskaitė, Algirdas Žalimas, Rasa Sabaliauskaitė, Kristina Žukauskaitė, Mantas Trakymas, Jurgita Ušinskienė, Albertas Ulys, Sonata Jarmalaitė","doi":"10.1007/s00432-025-06162-5","DOIUrl":"10.1007/s00432-025-06162-5","url":null,"abstract":"<p><strong>Purpose: </strong>Small renal masses (SRMs) SRMs are a heterogeneous group of small kidney lesions. Currently, the genomic landscape of SRMs is understudied, and clinically relevant tools for malignancy detection and fast tumor growth prediction are lacking. The aim of the study was to evaluate whether mutations in SRMs are associated with increased risk of renal cell carcinoma (RCC) or aggressive tumors.</p><p><strong>Methods: </strong>In this pilot study, 52 patients with SRMs were divided based on tumor histology into RCC and benign tumors, while RCC cases were divided into fast-growing and slow-growing tumor groups. Tissue biopsy samples evaluated for mutations in 51 cancer hotspot genes using next generation sequencing and qPCR. Non-benign mutations were tested for associations with RCC and clinical features. Receiver operating curve analysis used for evaluation of mutation biomarker models prediction of RCC and fast-growing tumors.</p><p><strong>Results: </strong>75% of SRMs harbored non-synonymous alterations in 16/51 genes. 38.5% of detected mutations were listed in ClinVar and correlated with smaller SRM volume (p = 0.023). KRAS, VHL, HNF1A, TP53, and ATM mutations were predominantly detected in RCC rather than benign SRMs (p = 0.046). SRMs with pathogenic mutations were at three times higher risk of being RCC and four times higher risk of fast growth.</p><p><strong>Conclusion: </strong>Genomic biomarkers may improve risk stratification and management of patients with SRMs, however a more extensive genomic analysis of SRMs is still needed.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 3","pages":"118"},"PeriodicalIF":2.7,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11928375/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143676969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elevated VRK1 levels after androgen deprivation therapy promote prostate cancer progression by upregulating YAP1 expression.","authors":"Yibo Meng, Jianchao Ge, Cheng Zhou, Hangbin Ma, Chenchen Chen, Yinghao Zhou, Xuetao Hu, Yaozong Xu, Xilong Wang, Guowei Shi, Wandong Yu, Jun Zhang","doi":"10.1007/s00432-025-06168-z","DOIUrl":"10.1007/s00432-025-06168-z","url":null,"abstract":"<p><strong>Purpose: </strong>Vaccinia-related kinase 1 (VRK1) is a serine-threonine kinase involved in the proliferation and migration of various cancer cells. However, its role in prostate cancer (PCa), particularly in the development of therapeutic resistance, remains unclear.</p><p><strong>Methods: </strong>We established an androgen-independent PCa cell line derived from LNCaP prostate cancer cells and conducted transcriptome and proteome sequencing together with bioinformatic analyses of large clinical sample databases to investigate the potential role of VRK1 in PCa progression. The correlation between VRK1 and androgen receptor (AR) signaling was evaluated under simulated clinical treatment conditions. The effects of VRK1 on cell proliferation were assessed in vitro and in vivo using Cell Counting Kit-8 and colony formation assays. Additionally, proteome and transcriptome sequencing, combined with rescue experiments were performed to explore VRK1-regulated signaling pathways related to cell proliferation and therapeutic resistance.</p><p><strong>Results: </strong>VRK1 expression was elevated during the progression of androgen-dependent prostate cancer to castration-resistant prostate cancer under therapeutic conditions, and high VRK1 expression was associated with a poor prognosis in patients with PCa. VRK1 was regulated by AR signaling, and its silencing suppressed PCa cell proliferation both in vitro and in vivo. VRK1 drove cell proliferation and therapeutic resistance in PCa by modulating yes-associated protein 1 (YAP1).</p><p><strong>Conclusions: </strong>VRK1 serves as a prognostic marker in PCa, regulated by AR signaling. VRK1 depletion inhibited cell proliferation both in vitro and in vivo, while elevated VRK1 upregulated YAP1, promoting cell proliferation and therapeutic resistance.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 3","pages":"116"},"PeriodicalIF":2.7,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11926012/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143669957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}